Science & Technology, Life Sciences & Biomedicine, Cardiac & Cardiovascular Systems, Cardiovascular System & Cardiology, Pulmonary arterial hypertension, Treatment, Guidelines, CALCIUM-CHANNEL BLOCKERS, DOUBLE-BLIND, PORTOPULMONARY HYPERTENSION, EISENMENGER-SYNDROME, INHALED ILOPROST, PHOSPHODIESTERASE-5 INHIBITOR, EPOPROSTENOL THERAPY, EXERCISE CAPACITY, BOSENTAN THERAPY, CONTROLLED-TRIAL, Female, Germany, Humans, Hypertension, Pulmonary, Practice Guidelines as Topic, Pregnancy, Pregnancy Complications, Pulmonary Medicine, Cardiovascular System & Hematology, 1102 Cardiorespiratory Medicine and Haematology
The 2009 European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension have been adopted for Germany. The guidelines contain detailed recommendations on the diagnosis of pulmonary hypertension (PH). However, the practical implementation of the European Guidelines in Germany requires the consideration of several country-specific issues and already existing novel data. This requires a detailed commentary to the guidelines, and in some aspects an update already appears necessary. In June 2010, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany. This conference aimed to solve practical and controversial issues surrounding the implementation of the European Guidelines in Germany. To this end, a number of working groups was initiated, one of which was specifically dedicated to the treatment of pulmonary arterial hypertension (PAH). This commentary describes in detail the results and recommendations of the working group on treatment of PAH which were last updated in October 2011.